Anatoliy Novyk, founder and president of SMC Ecopharm, the only Ukrainian pharmaceutical company to be exclusively focused on its own original drug development, provides insights into Ecopharm’s promising expansion strategy, which should be significantly propelled by the company’s upcoming GMP-certified manufacturing plant. He also provides an in-depth look into their own new drugs made on the basis of the active substance proteflazidum that can be successfully used in the treatment of diseases caused by DNA and RNA viruses.
Could you introduce the company that you founded in 1998 to our international readers as well as the main milestones achieved throughout the years?
"We have invested more than $5 million into construction of our own pharmaceutical facility that will be certified by the European GMP standards and will, according to the schedule, start operating just in the first half of 2018."
